Moderna Q1 2026 slides: revenue surges 260%, litigation weighs

Moderna Inc. (NASDAQ:MRNA) presented its first-quarter 2026 financial results on May 1, 2026, revealing dramatic revenue growth driven by international partnerships while absorbing a substantial litigation settlement that masked underlying operational improvements. The biotech company’s shares rose 1.63% in premarket trading to $46.69, reflecting investor focus on the company’s adjusted performance and expanding product pipeline.

Moderna reported total revenue of $389 million for the first quarter, representing a 260% increase from $108 million in the same period last year. Net product sales reached $352 million, up 309% year-over-year, with international markets accounting for 80% of quarterly revenue as the company’s strategic partnerships, particularly in the United Kingdom, began delivering results.

As detailed in the company’s financial summary, the quarter demonstrated significant cost discipline despite headline losses.

However, the company’s bottom line reflected a substantial one-time charge. Moderna reported a GAAP net loss of $1.343 billion, or $3.40 per share, compared to a loss of $971 million in the prior-year quarter. The widened loss was primarily attributable to an $878 million litigation settlement charge related to Arbutus patent disputes, which was recorded in cost of sales.

Excluding the litigation settlement, Moderna’s adjusted net loss improved significantly to $465 million, representing a 52% improvement compared to the first quarter of 2025. The company emphasized its continued financial discipline, reducing adjusted cash costs by 26% year-over-year.

The company’s comprehensive financial breakdown revealed improving operational metrics beneath the litigation charge impact.

Research and development expenses declined 24% to $649 million from $856 million in the prior-year period, reflecting the company’s portfolio prioritization efforts. Total operating expenses on an adjusted basis decreased 22% to $899 million, demonstrating progress toward the company’s cost efficiency targets.

Cash, cash equivalents, and investments stood at $7.5 billion as of March 31, 2026, down from $8.1 billion at year-end 2025. The $600 million decline reflected operational cash usage and the litigation settlement payment.

Moderna reiterated its full-year 2026 financial framework, projecting revenue growth of up to 10% compared to 2025 levels. The company’s outlook presentation detailed expectations across key financial metrics.

For the second quarter, Moderna expects revenue between $50 million and $100 million, with an approximately even split between U.S. and international markets. The company projects year-end cash and investments of $4.5 billion to $5.0 billion, excluding any further drawdowns from its remaining $900 million credit facility.

The revenue outlook by geography shows the company’s strategic shift toward international markets while maintaining U.S. presence.

The first quarter marked significant regulatory progress for Moderna’s infectious disease vaccine portfolio. The company outlined key achievements across its commercial and late-stage pipeline.

The European Union approved mNEXSPIKE, Moderna’s COVID-19 vaccine, for individuals aged 12 and older, and mCOMBRIAX, the company’s combination influenza and COVID-19 vaccine, for individuals aged 50 and older. These approvals represent important geographic expansion opportunities and validate Moderna’s combination vaccine strategy.

The company’s seasonal influenza vaccine, mRNA-1010, has a PDUFA action date of August 5, 2026, in the United States, representing a potentially significant market opportunity beyond COVID-19 vaccines.

Moderna’s approved infectious disease vaccine portfolio now spans multiple indications with expanding geographic reach.

The late-stage pipeline continues advancing with the norovirus vaccine candidate fully enrolled in its second Northern Hemisphere season of Phase 3 evaluation.

Moderna presented its strategic roadmap for revenue growth through 2028, highlighting diversification across therapeutic areas and geographic markets.

The company’s growth strategy layers multiple revenue drivers across infectious disease vaccines, oncology therapeutics, rare disease treatments, and geographic expansion through strategic partnerships. Near-term drivers include the recently approved vaccines and partnerships in the UK, Canada, and Australia, while 2027-2028 catalysts include potential launches of intismeran in oncology, the flu vaccine, and rare disease therapeutic PA.

Moderna’s oncology portfolio, led by the personalized cancer vaccine intismeran autogene (mRNA-4157) in partnership with Merck, achieved notable progress during the quarter. The company initiated a Phase 3 Stage 1 trial in non-small cell lung cancer and announced an upcoming oral presentation at the American Society of Clinical Oncology (ASCO) meeting featuring five-year follow-up data from the Phase 2 adjuvant melanoma study.

The intismeran development program spans multiple tumor types and clinical stages.

Beyond intismeran, Moderna’s broader oncology pipeline showed advancement with mRNA-4359, a cancer antigen therapy, presenting new data at the American Association for Cancer Research (AACR) conference. The program is enrolling patients across multiple metastatic melanoma and non-small cell lung cancer cohorts.

Moderna’s rare disease therapeutics pipeline achieved a significant milestone as the propionic acidemia (PA) program reached target enrollment in its registrational Phase 2 study. The company indicated it is deferring the decision on a pivotal trial for its methylmalonic acidemia (MMA) program until PA readout data becomes available.

These programs represent Moderna’s expansion into enzyme replacement therapies using mRNA technology, potentially addressing significant unmet needs in rare metabolic disorders.

Looking ahead, Moderna outlined three key value drivers for 2026 encompassing commercial execution, regulatory approvals, and clinical milestones.

The company’s commercial and financial performance targets include achieving up to 10% revenue growth and maintaining its adjusted cash cost target of $4.2 billion. Potential regulatory approvals span multiple geographies for mNEXSPIKE, mCOMBRIAX, and the flu vaccine. Clinical milestones include multiple data readouts from the oncology portfolio, norovirus Phase 3 results, and the PA registrational study data.

Moderna’s first-quarter presentation emphasized operational discipline and pipeline progress while navigating the impact of significant one-time litigation costs. The 260% revenue growth and 26% reduction in adjusted cash costs demonstrate the company’s ability to execute on its strategic priorities despite ongoing profitability challenges.

The stock’s positive premarket reaction suggests investors are focusing on adjusted metrics that exclude the litigation charge and viewing the strong international revenue performance as validation of the company’s geographic expansion strategy. With a current ratio of 3.29 and $7.5 billion in cash and investments, Moderna maintains substantial financial flexibility to fund its diversified pipeline through multiple value inflection points expected in 2026 and beyond.

However, investors should note that the company faces continued cash consumption, with projected year-end cash declining to $4.5-5.0 billion, and remains dependent on successful product launches and pipeline advancement to achieve sustained profitability. The concentration of first-quarter revenue in international markets also highlights potential geographic risk if global demand patterns shift.

Full presentation:

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.